Today The Schaper Benz & Wise Investment Counsel Inc. WI Has $2,168,000 Position in Regeneron Pharmaceuticals, Inc. (REGN)

Today The Schaper Benz & Wise Investment Counsel Inc. WI Has $2,168,000 Position in Regeneron Pharmaceuticals, Inc. (REGN)

Schaper Benz & Wise Investment Counsel Inc. WI boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 59.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,392 shares of the biopharmaceutical company’s stock after buying an additional 2,007 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI’s holdings in Regeneron Pharmaceuticals were worth $2,168,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. BB&T Corp purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at $1,054,000. Jennison Associates LLC increased its stake in shares of Regeneron Pharmaceuticals by 4.5% in the third quarter. Jennison Associates LLC now owns 2,122,148 shares of the biopharmaceutical company’s stock valued at $853,146,000 after buying an additional 91,223 shares in the last quarter. San Francisco Sentry Investment Group CA purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at $233,000. NEXT Financial Group Inc increased its stake in shares of Regeneron Pharmaceuticals by 46.9% in the third quarter. NEXT Financial Group Inc now owns 360 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 115 shares in the last quarter. Finally, Capital Investment Counsel Inc purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at $386,000. Hedge funds and other institutional investors own 69.01% of the company’s stock.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down 0.34% during mid-day trading on Wednesday, hitting $346.76. 139,285 shares of the stock were exchanged. The firm has a 50-day moving average price of $370.60 and a 200 day moving average price of $388.85. Regeneron Pharmaceuticals, Inc. has a 12-month low of $325.35 and a 12-month high of $463.24. The company has a market capitalization of $36.35 billion, a PE ratio of 50.56 and a beta of 1.80.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, November 4th. The biopharmaceutical company reported $3.13 earnings per share for the quarter, beating analysts’ consensus estimates of $2.73 by $0.40. The business had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.29 billion. Regeneron Pharmaceuticals had a net margin of 16.52% and a return on equity of 21.51%. Regeneron Pharmaceuticals’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same period last year, the company posted $3.47 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post $11.63 earnings per share for the current year.

Several brokerages recently weighed in on REGN. J P Morgan Chase & Co set a $440.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Sunday. Cowen and Company reiterated a “market perform” rating and issued a $380.00 price objective (down from $400.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, January 11th. Leerink Swann restated an “outperform” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, January 10th. Wells Fargo & Company restated a “market perform” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, January 10th. Finally, Evercore ISI set a $421.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Sunday, January 8th. Fifteen research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $455.26.

In related news, Director Arthur F. Ryan sold 2,000 shares of the stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $429.34, for a total value of $858,680.00. Following the sale, the director now directly owns 36,500 shares in the company, valued at approximately $15,670,910. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Sanofi purchased 87,298 shares of the business’s stock in a transaction that occurred on Wednesday, January 11th. The stock was purchased at an average price of $369.71 per share, for a total transaction of $32,274,943.58. The disclosure for this purchase can be found here. Insiders sold a total of 7,125 shares of company stock worth $2,990,990 over the last quarter. 10.40% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Related posts

Leave a Comment